Gene: SP140L

93349
-
SP140 nuclear body protein like
protein-coding
2q37.1
Ensembl:ENSG00000185404 MIM:617747 Vega:OTTHUMG00000153730 UniprotKB:Q9H930
NC_000002.12
SNP Mapped
1   ANCO-SNPs
ND|AD
0   
NA (AD)  NA (ND)   (Frontal_Cortex)
3.045e-1 (AD)  3.144e-1 (ND)

ANCO-SNPs

SNP ID Position Alleles Trait Variation Type
rs6712333chr2:230365456 (GRCh38.p7)C>Talcohol dependence|nicotine dependenceSNV(Single Nucleotide Variation)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
SP1000.915
NLRC50.89
TRIM380.881
TRIM50.881
CIITA0.863
PARP140.863
CASP40.858
PARP120.857
IL150.855
LGALS90.854

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
WNT7A-0.468
KCNIP3-0.463
MYADML2-0.457
TMEM179-0.454
CPLX3-0.436
MARCH4-0.433
ATP2C2-0.43
SLC7A4-0.43
ASPDH-0.423
BCL11A-0.417

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C5116212-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [Particulate Matter results in decreased expression of SP140L mRNA]28655636
C5116212-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [Vehicle Emissions results in decreased expression of SP140L mRNA]28655636
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with belinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SP140L mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SP140L mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SP140L mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SP140L mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SP140L mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SP140L mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with belinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SP140L mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SP140L mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SP140L mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SP140L mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SP140L mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SP140L mRNA"27188386
D000082AcetaminophenAcetaminophen results in decreased expression of SP140L mRNA21420995
D000082AcetaminophenAcetaminophen results in increased expression of SP140L mRNA26690555
D018501Antirheumatic AgentsAntirheumatic Agents results in decreased expression of SP140L mRNA24449571
C487081belinostatbelinostat results in increased expression of SP140L mRNA26272509
C487081belinostat"[NOG protein co-treated with belinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SP140L mRNA"27188386
C006780bisphenol Abisphenol A promotes the reaction [SP140L protein binds to ESR1 protein]27156127
D016572CyclosporineCyclosporine results in increased expression of SP140L mRNA25562108
D003703DemecolcineDemecolcine results in increased expression of SP140L mRNA23649840
D002117CalcitriolCalcitriol results in increased expression of SP140L mRNA16002434|2159239
D002117Calcitriol[Testosterone co-treated with Calcitriol] results in increased expression of SP140L mRNA21592394
C118739entinostatentinostat results in increased expression of SP140L mRNA26272509|2718838
C118739entinostat"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SP140L mRNA"27188386
D005020Ethyl MethanesulfonateEthyl Methanesulfonate results in increased expression of SP140L mRNA23649840
D005557FormaldehydeFormaldehyde results in increased expression of SP140L mRNA23649840
D008741Methyl MethanesulfonateMethyl Methanesulfonate results in increased expression of SP140L mRNA23649840
D009532NickelNickel results in increased expression of SP140L mRNA24768652|2558310
C496932panobinostat"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SP140L mRNA"27188386
C496932panobinostatpanobinostat results in increased expression of SP140L mRNA26272509
D052638Particulate Matter2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [Particulate Matter results in decreased expression of SP140L mRNA]28655636
D052638Particulate MatterParticulate Matter results in decreased expression of SP140L mRNA28655636
D011192Potassium DichromatePotassium Dichromate results in decreased expression of SP140L protein23718831
D012822Silicon DioxideSilicon Dioxide analog results in increased expression of SP140L mRNA25895662
D013739Testosterone[Testosterone co-treated with Calcitriol] results in increased expression of SP140L mRNA21592394
D013739TestosteroneTestosterone results in increased expression of SP140L mRNA21592394
C012589trichostatin A"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SP140L mRNA"27188386
C012589trichostatin Atrichostatin A results in increased expression of SP140L mRNA24935251|2627250
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SP140L mRNA"27188386
D014635Valproic AcidValproic Acid affects the expression of SP140L mRNA25979313
D014635Valproic AcidValproic Acid results in increased expression of SP140L mRNA24383497|2493525
D001335Vehicle Emissions2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [Vehicle Emissions results in decreased expression of SP140L mRNA]28655636
D001335Vehicle EmissionsVehicle Emissions results in decreased expression of SP140L mRNA28655636
D014750VincristineVincristine results in increased expression of SP140L mRNA23649840
C111237vorinostat"[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SP140L mRNA"27188386

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0000981RNA polymerase II transcription factor activity, sequence-specific DNA binding-ISM19274049  
GO:0003677DNA binding-IEA-  
GO:0046872metal ion binding-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0006357regulation of transcription by RNA polymerase II-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0016604nuclear body-IEA-  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal